Search Results for “ oncology” – Page 59 – media

Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets

Vividion to receive $101 million in upfront payment, including equity investment Collaboration utilizes Vividion's unique proteome-wide ligand and target discovery platform
- Source: prnewswire
- 450
- March 7, 2018
Celgene
Global health startup PharmaJet with needle-free injectable device close to raising $5M

Needle-free drug injection company PharmaJet is close to completing a $5 million fundraising round of financing that would fund the production of 5 million syringes to deliver the polio vaccine.
- Source: MedCityNews
- 1,019
- March 7, 2018
Company Insight medical device products WHO
TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®) and TESARO’s PARP-inhibitor ZEJULA® (niraparib) in patients with metastatic bladder cancer.
- Source: ir.tesarobio
- 774
- March 6, 2018
antibody bladder cancer Market Views oncology
Lilly’s Verzenio bags third breast cancer nod

Eli Lilly’s Verzenio has been given another green light in the US for breast cancer, significantly expanding the drug’s treatment scope.
- Source: Pharmatimes
- 608
- March 1, 2018
breast cancer New Approvals
Viela Bio Spins Out of MedImmune; Raises Up to $250 Million in Series A Financing, 6 Dimensions Capital Leads Investment

Viela Bio announced today that it has incorporated as an independent, inflammation - and autoimmunity - focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca. Viela Bio will primarily focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of the diseases.
- Source: finance.yahoo
- 475
- March 1, 2018
autoimmunity inflammation Market Views
Navigating the Legal Complexities of a Digital Health Transaction

Whatever the long-term future for life sciences, in house lawyers and their business counterparts as well as outside advisors who are able to navigate the convergence of business and legal issues surrounding the life sciences and technology industries will have a competitive advantage over those who ignore the parallel convergences that are taking place, continuing to focus instead on life sciences and technology as distinct and separate fields.
- Source: Corporate Council - Law.com
- 538
- March 1, 2018
big data digital health healthcare technologies and innovations Market Views
Researchers develop new technology platform for cancer immunotherapy

Johns Hopkins researchers have invented a new class of immunotherapeutic agents that are more effective at harnessing the power of the immune system to fight cancer. Their approach results in significant inhibition of tumor growth, even against cancers which do not respond to existing immunotherapies used in the clinic. In collaboration with Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery, the team reports their results this week in Nature Communications.
- Source: immunotherapies
- 519
- February 27, 2018
cancer immunotherapies Researches
Gilead links with Sangamo in gene therapy alliance

Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
- Source: drugdu
- 546
- February 26, 2018
cancer engineered cell therapies Gilead Market Views
Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

Merck & Company is driving forward in its quest to develop a premier immuno-oncology pipeline. The company plunked down $394 million to acquire Australia-based Viralytics Ltd and its oncolytic immunotherapy treatments.
- Source: Biospace;
- 726
- February 26, 2018
immuno-oncology pipelin immunotherapy Market Views Merk
Merck’s ERK inhibitor shows promise in combo against resistant cancers

One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of many cancers.
- Source: fiercebiotech
- 547
- February 23, 2018
cancer drugs Company Insight inhibitor

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.